I-Mab
NASDAQ:IMAB

Watchlist Manager
I-Mab Logo
I-Mab
NASDAQ:IMAB
Watchlist
Price: 0.9397 USD -2.01% Market Closed
Market Cap: 76m USD
Have any thoughts about
I-Mab?
Write Note

I-Mab
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

I-Mab
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
I-Mab
NASDAQ:IMAB
Gross Profit
ÂĄ27.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Gross Profit
ÂĄ14.7B
CAGR 3-Years
108%
CAGR 5-Years
67%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Gross Profit
ÂĄ4.5B
CAGR 3-Years
34%
CAGR 5-Years
45%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Gross Profit
ÂĄ3.3B
CAGR 3-Years
21%
CAGR 5-Years
19%
CAGR 10-Years
22%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Gross Profit
ÂĄ11.7B
CAGR 3-Years
3%
CAGR 5-Years
26%
CAGR 10-Years
38%
Imeik Technology Development Co Ltd
SZSE:300896
Gross Profit
ÂĄ2.7B
CAGR 3-Years
61%
CAGR 5-Years
57%
CAGR 10-Years
N/A
No Stocks Found

I-Mab
Glance View

Market Cap
76m USD
Industry
Biotechnology

I-Mab operates as a clinical stage biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-01-17.

IMAB Intrinsic Value
0.7454 USD
Overvaluation 21%
Intrinsic Value
Price

See Also

What is I-Mab's Gross Profit?
Gross Profit
27.6m CNY

Based on the financial report for Dec 31, 2023, I-Mab's Gross Profit amounts to 27.6m CNY.

Back to Top